loading page

Programmed Death Cell Ligand-1 Expression in Lymphoepithelioma-like Carcinoma of the Bladder: A Case Report
  • Ahmet Serdar Teoman,
  • Hatice Kucuk,
  • Gizem Teoman
Ahmet Serdar Teoman
Trabzon Fatih State Hospital

Corresponding Author:[email protected]

Author Profile
Hatice Kucuk
SUB Kanuni Training and Research Hospital
Author Profile
Gizem Teoman
SUB Kanuni Training and Research Hospital
Author Profile


Introduction: Lymphoepithelioma-like carcinoma of the bladder (LELC-B) is a rare variant of bladder tumors and until today only 145 cases are reported in the literature. It has a worse prognosis and survival rates in comparison with papillary muscle invasive tumors. However, general treatment options including radical cystectomy, chemotherapy and radiotherapy; discovery of the programmed death cell ligand-1 (PDL-1) expression for LELC-B recently, may lead a novel immunohistochemical diagnostic method and PDL-1 immunostaining may increase detection of this variant. Case Presentation: A 72-year-old male patient with lower urinary tract symptoms is diagnosed as bladder tumor with imaging modalities. After transurethral resection of this bladder tumor, immunopathological diagnose was muscle invasive bladder tumor predominantly lymphepithelioma like carcinoma of the bladder. PDL-1 immunostaining was also highly positive(>%50). Discussion/Conclusion: Lymphoepithelioma-like cancer of bladder is an undifferantiated aggressive rare variant of bladder cancers. Its identifiability may increase with detection of PDL-1 expression. In the future, that might pave a road to targeted immunotherapies as an alternative for selected patients.